Compare ANIK & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIK | ACB |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.9M | 232.3M |
| IPO Year | 1996 | 2016 |
| Metric | ANIK | ACB |
|---|---|---|
| Price | $20.25 | $3.97 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 85.3K | ★ 1.1M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,819,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.44 | $8.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.01 | $2.56 |
| 52 Week High | $22.88 | $6.36 |
| Indicator | ANIK | ACB |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 45.18 |
| Support Level | $20.13 | $3.75 |
| Resistance Level | $22.70 | $4.20 |
| Average True Range (ATR) | 0.80 | 0.17 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 79.82 | 19.88 |
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.